Ask AI
ProCE Banner Activity

TROPION-Breast02: Safety Analyses of Dato-DXd vs Chemotherapy in Previously Untreated Patients With Advanced TNBC Not Suitable for Immunotherapy

Conference Coverage
Slideset

Additional safety analyses from the phase III TROPION-Breast02 evaluating datopotamab deruxtecan (Dato-DXd) vs investigator’s choice of chemotherapy show lower exposure adjusted incidence rates of adverse events and manageable safety in patients with locally recurrent/inoperable or metastatic TNBC not suitable for immunotherapy.

Released: December 22, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify subpopulations of patients with breast cancer most likely to benefit from a specific treatment plan based on predictive biomarkers

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with breast cancer
  • Evaluate new data on novel agents and therapeutic approaches for patients with breast cancer